Fentanyl Transdermal Patch

Contraindicated

Fentanyl Transdermal Patch Ensitrelvir Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Fentanyl Transdermal Patch Isocarboxazid Marplan An increased risk of CNS depression Details Fentanyl Transdermal Patch Levoketoconazole Recorlev Increased CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related adverse reaction Details Fentanyl Transdermal Patch Mifepristone Korlym Increased fentaNYL exposure and risk of adverse events Details Fentanyl Transdermal Patch Naltrexone ReVia Precipitation of opioid withdrawal symptoms; decreased opioid effectiveness Details Fentanyl Transdermal Patch Phenelzine Nardil An increased risk of serotonin syndrome Details Fentanyl Transdermal Patch Safinamide Xadago Increased risk of serotonin syndrome Details Fentanyl Transdermal Patch Samidorphan Decreased opioid efficacy and precipitation of opioid withdrawal Details Fentanyl Transdermal Patch Tranylcypromine Parnate Potentiation of opioid effects, an increased risk of serotonin syndrome and an increased risk of CNS depression Details

Major

Fentanyl Transdermal Patch Abametapir Increased exposure of CYP3A4 substrate Details Fentanyl Transdermal Patch Acepromazine PROMACE Increased risk of profound sedation, respiratory depression, hypotension, coma and death Details Fentanyl Transdermal Patch Aclidinium Tudorza Increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus Details Fentanyl Transdermal Patch Alefacept Decreased fentanyl plasma concentrations Details Fentanyl Transdermal Patch Alfentanil Increased risk of respiratory and CNS depression and an increased risk of serotonin syndrome Details Fentanyl Transdermal Patch Almotriptan Increased risk of serotonin syndrome Details Fentanyl Transdermal Patch Alprazolam Xanax Increased risk of profound sedation, respiratory depression, hypotension, coma and death Details Fentanyl Transdermal Patch Amantadine Increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus Details Fentanyl Transdermal Patch Amifampridine Increased risk of seizures Details Fentanyl Transdermal Patch Amiloride Reduced diuretic efficacy Details Fentanyl Transdermal Patch Amineptine Increased risk of serotonin syndrome Details Fentanyl Transdermal Patch Amiodarone Nexterone Cardiac toxicity (low cardiac output) and an increased risk of fentanyl toxicity (CNS depression, respiratory depression) Details Fentanyl Transdermal Patch Amitriptyline Elavil Increased risk of paralytic ileus and an increased risk of serotonin syndrome Details Fentanyl Transdermal Patch Amitriptylinoxide Increased risk of serotonin syndrome Details Fentanyl Transdermal Patch Amobarbital Amytal Increased risk of profound sedation, respiratory depression, hypotension, coma and death Details Fentanyl Transdermal Patch Amoxapine Increased risk of paralytic ileus and an increased risk of serotonin syndrome Details Fentanyl Transdermal Patch Amphetamine Dexedrine An increased risk of serotonin syndrome Details Fentanyl Transdermal Patch Amprenavir Increased fentaNYL exposure and an increased risk of prolonged opioid effects Details Fentanyl Transdermal Patch Anileridine Increased risk of respiratory and CNS depression and an increased risk of serotonin syndrome Details Fentanyl Transdermal Patch Apalutamide Erleada Reduced exposure of fentaNYL, reduced efficacy of fentaNYL and/or onset of opioid withdrawal symptoms Details Fentanyl Transdermal Patch Aprepitant Aponvie Increased fentaNYL exposure and an increased risk of prolonged opioid effects Details Fentanyl Transdermal Patch Aripiprazole Abilify Increased risk of profound sedation, respiratory depression, hypotension, coma and death Details Fentanyl Transdermal Patch Aripiprazole Lauroxil Aristada Increased risk of profound sedation, respiratory depression, hypotension, coma and death Details Fentanyl Transdermal Patch Armodafinil Nuvigil Reduced exposure of fentaNYL, reduced efficacy of fentaNYL and/or onset of opioid withdrawal symptoms Details Fentanyl Transdermal Patch Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Fentanyl Transdermal Patch Asenapine Saphris Increased risk of profound sedation, respiratory depression, hypotension, coma and death Details Fentanyl Transdermal Patch Atazanavir Reyataz Increased fentaNYL exposure and an increased risk of prolonged opioid effects Details Fentanyl Transdermal Patch Atropine Atropen Increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus Details Fentanyl Transdermal Patch Avacopan Tavneos Increased exposure to CYP3A4 substrate Details Fentanyl Transdermal Patch Baclofen Fleqsuvy Increased risk of profound sedation, respiratory depression, hypotension, coma and death Details Fentanyl Transdermal Patch Belladonna Increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus Details